The Board of Directors of Milestone Medical Inc. (WAR: MMD, “the Company”, “the Issuer”), today announced it has completed enrollment in its COMPASS Study (CompuFlo® Assessment Study), a randomized, controlled, parallel group, multicenter, pivotal study to assess the safety and effectiveness of the epidural space verification with the CompuFlo® Epidural Computer Controlled System. The clinical trial for the epidural instrument reached its target of enrolling 400 patients and consists of two separate arms: (i) pain management; and (ii) labor and delivery. Both arms will be compared against the current medical standards of care. The goal of the pivotal IDE clinical trial is to demonstrate the accuracy of the CompuFlo technology in identifying and confirming the epidural space location.
The Board of Directors of the Issuer is pleased to achieve the enrollment target and expects to complete the trial in the coming weeks.
Legal basis: § 3 subparagraph 1 of the Exhibit 3 to the Alternative Trading System Rules “Current and Periodical Information in the Alternative Trading System on the NewConnect Market".
Osoby reprezentujące spółkę:
Joseph D'Agostino - Chief Financial Officer